KRAS and non-small cell lung carcinoma: Despite major improvements made with early detection, and increased knowledge and identification of actionable tumor biomarkers, KRAS-driven lung adenocarcinoma still represents a commonly diagnosed form of NSCLC for which there are no targeted agents.